DPP4 and Hypoglycemia: Dipeptidyl peptidase-4 (DPP-4) inhibitors have emerged as an essential class of glucose-lowering drugs in managing diabetes, given their favorable profiles in terms of weight neutrality, low hypoglycemia risk, and, for many drugs in this class, ease of use in patients with varying renal function.